Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...
New findings could help identify patients likely to become resistant to anti-cancer drugs and aid exploring different ways to ...
Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with ...
BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...
Therapeutics announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating ...
Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has accepted Talzenna (talazoparib) in combination with ...
LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor in HRD (homologous recombination deficiency) cancers.